(Credit-Canva)
Not too long ago, people believed that mental health and any kind of odd behavior meant you were not of a sound mind, whether you were feeling constantly lethargic and sad, you were treated as if you had lost your sanity. But there has been a lot of progress regarding this, with people understanding that it is a much broader spectrum. The old methods of treating the mentally ill are also discontinued and frowned upon as they were very taxing and harmful for people. Mental health has been at the forefront of many medical conversations these days, while there are many people who still do not believe in its validity, researchers and medical professionals have been working tirelessly to make mental healthcare more accessible to everyone.
But as we have slowly lost the stigma surrounding mental health by educating ourselves and understanding not to treat others who struggle with it as less than, there has been great progress, in terms of new researches and better treatment as well! Depression is a widely discussed topic, with many people bringing up their own struggles with it and how it affected them. But what a lot of people do not know is that depression can manifest as physical symptoms as well. New research shows that it is not something that only affects your psychology, but can have a big effect on your entire body!
New research shows that depression isn't just about feeling sad, it affects your whole body. It can actually speed up the development of long-term physical health problems as you get older. Think of it like this, if you're constantly stressed and down, your body works harder and can wear out faster. A study from the University of Edinburgh found a strong link between having a history of depression and getting chronic physical illnesses earlier in life. This means it's really important to see depression as a serious health problem that affects everything, not just your mood. Taking care of your mental health is like taking care of your physical health too.
The researchers, led by Kelly Fleetwood, found that people who had been depressed were much more likely to develop serious long-term illnesses like heart disease and diabetes. These aren't just minor problems, they're big health issues that can really change your life. The study also showed that these illnesses appeared about 30% earlier in people who had been depressed compared to those who hadn't. So, someone with depression might start having heart problems or diabetes in their 50s or 60s, while someone who'd never been depressed might not have these problems until much later, or maybe not at all. This shows how important it is to get help for depression early on.
The study found some common health problems that were more likely to happen to people who had been depressed. These included osteoarthritis which is a joint problem, high blood pressure, and GERD which is a stomach problem. For example, about 16 out of every 100 people with a history of depression got osteoarthritis, compared to about 13 out of every 100 people without depression. The same kind of increase was seen for high blood pressure and GERD. These numbers might seem small, but they show a real increase in risk for people with depression, which again highlights how connected mental and physical health are.
The researchers believe that because depression affects so much of the body, it should be treated as a "whole-body" illness. This means doctors and other healthcare providers need to look at the whole person, not just one problem at a time. Right now, many healthcare systems are set up to treat one illness at a time. But this study shows that someone with depression might also have heart problems or diabetes, and all of these things need to be treated together. The researchers are saying we need a better way of providing healthcare, where mental and physical health are both given the same importance. This would lead to much better results for people.
Credits: Canva
The Centers for Disease Control and Prevention (CDC) released three reports on Thursday that highlighted the clusters of medetomidine-related cases in Chicago, Philadelphia, and Pittsburgh. These reports have raised alarm about the growing presence of this drug in street opioids and the potential complications it brings to treatment and recovery.
As per the American College of Medical Toxicology (ACMT), it is an alpha-2 agonist, similar to clonidine and xylazine, that is used clinically as a sedative and analgesic. It is categorized as an NPS due to its novelty in use. The CDC in its Morbidity and Mortality Weekly Report notes that it is a canine veterinary agent used for its anesthetic and analgesic properties.
However, the National Library of Medicine's study titled Classics in Chemical Neuroscience: Medetomidine has noted that this drug "has recently been detected in the illicit drug supply alongside fentanyl, xylazine, cocaine, and heroin, producing pronounced sedative effective that are not reversed by naloxone."
As per the latest CDC report released on May 1, twelve confirmed and 26 probable cases of medetomidine-involved overdose occurred in Chicago. Fentanyl was present in all blood specimens and drug samples that tested positive for medetomidine.
It was first identified in North America’s illicit opioid market in 2022, medetomidine is now showing up more frequently in mixtures with synthetic opioids—particularly fentanyl, the drug driving most overdose deaths in the U.S.
In May 2023, Chicago officials noticed a spike in overdose cases where naloxone—the standard overdose-reversal medication—did not work as expected. After investigation, the city's health department confirmed 12 cases involving medetomidine, with over 160 more suspected or probable cases, including one potential death. This marks the largest known medetomidine cluster to date.
The two other CDC reports focused on medetomidine withdrawal. In Philadelphia, testing revealed medetomidine in 72% of illegal opioid samples collected in late 2023, overtaking xylazine in frequency. Patients exposed to medetomidine experienced a distinctive type of drug withdrawal that didn’t respond to usual medications for fentanyl or xylazine. However, a related medication called dexmedetomidine showed some success in managing symptoms.
Pittsburgh reported 10 similar cases around the same time, suggesting the issue is not isolated to one area but may be spreading through regional drug supplies.
The presence of sedatives like medetomidine in illicit opioids creates several public health challenges:
Reduced effectiveness of naloxone: Standard treatment protocols for overdoses may not work when sedatives are involved, increasing the risk of death.
Complicated withdrawals: The addition of new, unregulated substances alters the withdrawal process, often making it harder to treat.
Lack of awareness and testing: Many emergency responders and clinics do not routinely test for medetomidine, which could delay proper care.
This development adds a new layer to the already complex U.S. opioid crisis. As drug suppliers continue to mix opioids with a variety of sedatives and adulterants, health officials face an evolving battle. Experts stress the importance of broader toxicology screening, continued research, and expanding the availability of alternative treatments like dexmedetomidine.
While medetomidine isn’t yet as widespread as fentanyl or xylazine, its growing presence in cities like Chicago, Philadelphia, and Pittsburgh points to a potentially dangerous trend—one that will require urgent attention from both medical professionals and policymakers.
Credit: Canva
Receiving a vaccine booster in the same arm as the first dose triggers a faster and stronger immune response and helps the body build protection faster, a new study from Australian scientists has revealed. The findings could help improve vaccine strategies and may eventually lead to vaccines that need fewer boosters. The study was published in the journal Cell and finds that the immune system responds more quickly when both doses are given in the same arm.
Researchers discovered this effect first in mice, then confirmed it in a clinical study involving 30 people who received the Pfizer COVID-19 vaccine. Those who had both doses in the same arm developed faster and more effective protection, especially against COVID-19 variants like Delta and Omicron. While both groups ended up with similar antibody levels after four weeks, the same-arm group gained protection more quickly, a potential game-changer during pandemic outbreaks.
"If you've had your COVID jabs in different arms, don't worry, our research shows that over time the difference in protection diminishes," said the study's co-senior author, Mee Ling Munier from the Kirby Institute.
Credit: Canva
Microplastics pose a danger to the heart. While there is enough evidence to show that they clog arteries and exacerbate the risk of stroke, recent research has found that these teeny particles of plastic can trigger cardiovascular diseases. It is estimated that chemicals in plastic were linked to nearly 350,000 heart disease deaths across the world in 2018. Adding to that, is this study published in the journal eBioMedicine, which estimated that roughly 13 per cent of cardiovascular deaths among 55- to 64-year-olds worldwide that year could be attributed to phthalates.
Where Are Phthalates are esters of phthalic acids, which are added to plastics to increase their flexibility, transparency, durability, and longevity. They are found in personal care products like shampoos and lotions as well as in food containers and packaging. It is also possible to injest them through food, absorb them through skin from products containing them or breathe them from dust.
Some studies have shown an association between phthalates and cardiovascular disease, but there isn’t strong evidence to show that the chemicals directly cause heart issues, said Sung Kyun Park, a professor of epidemiology and environmental sciences at the University of Michigan School of Public Health. However, there is enough evidence that states that phthalates increase the risk of metabolic disorders like obesity and Type 2 diabetes, which can cause cardiovascular disease. One way phthalates may do this is by increasing oxidative stress—cell and tissue damage that happens when there are too many unstable molecules in the body—and by promoting inflammation.
Microplastics are extremely small particles—often less than five millimetres in size—created when larger pieces of plastic break down. They can enter the human body in multiple ways: through the air we breathe, the food we eat, and even skin contact. An even smaller subset, known as nanoplastics, measures under 1,000 nanometers and is completely invisible to the naked eye. Because of their minuscule size, these particles can infiltrate tissues, organs, and potentially disrupt biological functions.
Amid growing concerns about microplastic contamination, especially in drinking water, scientists have been working on practical ways to mitigate exposure. In 2024, a research team from Guangzhou Medical Centre made a breakthrough. They discovered that a common household activity—boiling water—can significantly reduce microplastic content in tap water.
According to the team, combining boiling with basic filtration can remove up to 90% of nanoplastic and microplastic particles (NMPs) from household water. However, the method’s effectiveness varied depending on the type of water used. In areas where tap water contains higher mineral content, commonly referred to as "hard water," the technique proved especially efficient.
The secret lies in limescale. As hard water is heated, it forms limescale—a chalky white substance—which appears to create a sticky layer that traps microplastic fragments. Researchers found this natural process enhanced the removal of plastic particles from water, offering a practical and affordable solution for most households.
While more research is needed to fully understand the long-term health effects of microplastics, early evidence suggests they may be more dangerous than previously thought—especially for cardiovascular health.
© 2024 Bennett, Coleman & Company Limited